Cargando…
Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based p...
Autores principales: | Reig-López, Javier, Maldonado, María del Mar, Merino-Sanjuan, Matilde, Cruz-Collazo, Ailed M., Ruiz-Calderón, Jean F., Mangas-Sanjuán, Victor, Dharmawardhane, Suranganie, Duconge, Jorge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602742/ https://www.ncbi.nlm.nih.gov/pubmed/33076517 http://dx.doi.org/10.3390/pharmaceutics12100975 |
Ejemplares similares
-
Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167
in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry
por: Maldonado, María del Mar, et al.
Publicado: (2019) -
Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42
por: Medina, Julia I., et al.
Publicado: (2022) -
Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making
por: Reig-López, Javier, et al.
Publicado: (2021) -
Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022) -
Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment
por: García-Martínez, Teresa, et al.
Publicado: (2022)